Research Update CHF 02534 EY 4 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma

We have screened 58 dogs for the study. None of the dogs were enrolled due to the detection of metastatic disease during the screening process. Two other dogs were not screened due to the prior use of Yunnan Baiyao beyond the 24-hour limit allowed, and another owner cancelled the morning of the screening for unknown reasons. We have enrolled 19 dogs to date, bringing enrollment to 95% of the dogs proposed for the study. Continue reading “Research Update CHF 02534 EY 4 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma”

Research Update CHF 02806-MOU EY3: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up

The goal for this project is to develop a reliable, accessible, and actionable test to identify dogs at risk for hemangiosarcoma during the earliest stages of disease and to use a strategic, rationally designed approach to prevent its occurrence in these high-risk dogs before it becomes clinically detrimental and life-threatening. Continue reading “Research Update CHF 02806-MOU EY3: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up”

Research Update CHF 02759 FINAL: Reprogramming the Tumor Immune Niche in Canine Hemangiosarcoma

We have made significant progress toward Objective 1 and 2 for this project. The PI, Dr. Kim has established a new laboratory for veterinary oncology research in the Department of Small Animal Clinical Sciences, at the University of Florida College of Veterinary Medicine. Over the past six months, we have successfully transferred our expertise in hemangiosarcoma research and finalized work to achieve the project objectives in the new institute. We have enhanced our knowledge of how PIK3CA gene mutations influence cellular and molecular behaviors of canine hemangiosarcoma cells.

Continue reading “Research Update CHF 02759 FINAL: Reprogramming the Tumor Immune Niche in Canine Hemangiosarcoma”

Research Update CHF 02519 Final: Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas Within and Between Geographic Locations

We gained substantial and seemingly important information relative to the aims of this study. We were able to obtain the initial set of samples on April 26, 2018 so we had a short delay in starting this study. Subsequently, the COVID epidemic and loss of research personal resulted in repeated interruptions in our research efforts. After completing all Year I study aims, we continued to work on improvements in immunohistochemistry and FISH localization of Bartonella organisms within various cell types. Continue reading “Research Update CHF 02519 Final: Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas Within and Between Geographic Locations”

Research Update CHF 02534 EY 3 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma

We opened the trial on July 1, 2019. As of June 27, 2021, we have enrolled 18 dogs in the study and no dose limiting toxicities within the initial 21-day assessment period have been observed. Based on these results, we are continuing to enroll dogs at the highest dose of propranolol (1.3 mg/kg) being tested.

Propranolol and doxorubicin levels in the blood from all of the dogs enrolled to date have been analyzed. Continue reading “Research Update CHF 02534 EY 3 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma”

Research Update CHF 02759 Mid-year 2: Reprogramming the Tumor Immune Niche in Canine Hemangiosarcoma

We have made significant progress toward Objective 1 and 2 for this project. Over the past six months, we have continued work to examine molecular and functional changes induced by PIK3CA gene mutations in canine HSA cells. Our data reveal that PI3K inhibitors increase DNA damage greater in HSA cells with PIK3CA mutations than cells without the mutations (i.e., wild-type cells), which depends on a drug dose. Continue reading “Research Update CHF 02759 Mid-year 2: Reprogramming the Tumor Immune Niche in Canine Hemangiosarcoma”

Research Update CHF 02534 MY 3 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma

We opened the trial on July 1, 2019. As of June 27, 2021, we have enrolled 18 dogs in the study and no dose limiting toxicities within the initial 21-day assessment period have been observed. Based on these results, we are continuing to enroll dogs at the highest dose of propranolol (1.3 mg/kg) being tested. Continue reading “Research Update CHF 02534 MY 3 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma”

Research Update CHF 02806-MOU MY2: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up

The goal of this project is to develop a reliable, accessible, and actionable test to identify dogs at risk for hemangiosarcoma during the earliest stages of the disease and to use a strategic, rationally designed approach to prevent its occurrence in these high-risk dogs before it becomes clinically detrimental and life-threatening. Continue reading “Research Update CHF 02806-MOU MY2: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up”

Research Update CHF 02624 Mid-year 3: Embracing Polygenicity of Common Complex Disease in Dogs: Genome-wide Association of Cruciate Ligament Rupture

We have met our Labrador Retriever recruitment for this study over the past year months. We will continue to complete DNA isolation and marker genotyping of the remaining dogs needed for the study as long as the genotyping service remains open under the Covid-19 pandemic. Public engagement with the project continues to be good. Continue reading “Research Update CHF 02624 Mid-year 3: Embracing Polygenicity of Common Complex Disease in Dogs: Genome-wide Association of Cruciate Ligament Rupture”